Table 2.

CTL of cancer patient kill tumor cells of various origins and types

Cell target	Tumor origin	hTRT expression*	HLA-A2†	Percent lysis‡
				CTL p540§	CTL p865
T2 + peptide		ND	Pos.	59	48
T2		ND	Pos.	11	4
MCF7	Breast	Pos.	Pos.	39	41
SKBR3		Pos.	Neg.	7	9
SW480	Colon	Pos.	Pos.	12	37
HCT011		Pos.	Neg.	9	6
H69	Lung	Pos.	Pos.	41	9
H146		Pos.	Neg.	11	5
624	Melanoma	Pos.	Pos.	48	39
1351		Pos.	Neg.	12	6
LnCap	Prostate	Pos.	Pos.	44	41
Pc3		Pos.	Neg.	9	5

Pos., positive; Neg., negative. 

^*hTRT expression of the tumor cells was determined by a PCR-based assay (TRAPeze, Intergen, Purchase, NY). 

^† Expression of HLA-A2 was measured by flow cytometry with the monoclonal antibody BB7.2. 

^‡ Cellular cytotoxicity was measured in a ⁵¹Cr-labeled release assay at an effector-to-target ratio of 50∶1. All tumor cell lines were incubated with 100 units/ml of recombinant IFN-γ for 48 h before the ⁵¹Cr-labeled release assay. 

^§ CTL lines 380.540.1 and 380.865.1 of patient were generated by immunization with p540 and p865, respectively.